Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Renovaro Inc. (RENB : NSDQ)

• Company Description    Renovaro Inc. includes RenovaroCube and Renovaro Biosciences. Renovaro Biosciences is an advanced cell-gene-immunotherapy company. Its lead candidate product is a therapeutic vaccine targeting cancers which are difficult to treat including pancreatic and potentially HNC, triple-negative breast cancer, and advanced liver cancer. Renovaro Inc., formerly known as Renovaro Biosciences Inc., is based in LOS ANGELES. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $0.30 Daily Weekly Monthly 20 Day Moving Average: 1,794,590 shares Shares Outstanding: 172.12 (millions) Market Capitalization: $51.15 (millions) Beta: 0.51 52 Week High: $2.10 52 Week Low: $0.27 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.71% -24.64% 12 Week -15.71% -29.10% Year To Date -64.43% -66.69%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2080 Century Park East Suite 906 - Los Angeles,CA 90067 USA ph: 305-918-1980 fax: - renb@mzgroup.us http://www.renovarogroup.com

• General Corporate Information    Officers Mark Dybul - Chief Executive Officer Rene Sindlev - Chairman Simon Tarsh - Interim Chief Financial Officer Gregg Alton - Director Jayne McNicol - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29350E104 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/25 Next Expected EPS Date: 10/09/25 Share - Related Items Shares Outstanding: 172.12 Most Recent Split Date: (:1) Beta: 0.51 Market Capitalization: $51.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/09/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.53 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: 100.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -60.38 12/31/24 - -61.84 ROA 06/30/25 - - 03/31/25 - -47.04 12/31/24 - -48.07 Current Ratio 06/30/25 - - 03/31/25 - 0.13 12/31/24 - 0.06 Quick Ratio 06/30/25 - - 03/31/25 - 0.13 12/31/24 - 0.06 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.56 12/31/24 - 0.52 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©